Currently in Orlando Florida the 2013 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium is in progress. There are a number of very interesting abstracts that pertain to those of us who have advanced prostate cancer. In the course of the next few days I will be reviewing a number of these that I [...]
Cancer chemotherapy agents historically have been administered intravenously or by an injection. In recent times there have been a number of emerging oral chemotherapy. Most of us strongly prefer the oral drugs as they are a convenient and noninvasive alternative to intravenous and injected therapies. Additionally, many of the intravenously delivered chemotherapy drugs target and [...]
Chemotherapy with Docetaxel is usually given on a once every three (3) week schedule of 75 mg/m2 administered intravenously + prednisolone (10 mg/day p.o.) for men with advanced prostate cancer. In the cases when the side effects are too difficult for a man to tolerate, the dose is often reduced to 50 mg/m2 administered intravenously [...]
I remember when I was first diagnosed with a prostate cancer recurrence, when I was told that I had advanced prostate cancer. More than any other times that I have been told I have cancer (I have melanoma, thyroid cancer, renal cancer and advanced prostate cancer) I felt the world stopped and my life was [...]
Cabozantinib (XL184) is an orally bioavailable tyrosine kinase inhibitor with activity against MET and vascular endothelial growth factor receptor 2. It is designed to target the men with castration resistant prostate cancer (CRPC). Results from a phase II randomized discontinuation trial with an expansion cohort of XL184 have recently been released. The trial included men [...]
I have said many times that one of the more important issues facing our use of Provenge is when to start it and how to sequence this treatment with the other newly approved agents that have recently become available for men with advanced prostate cancer. There is occasional conversation that Provenge is already antiquated due [...]
Sipuleucel-T (Provenge) is FDA approved after a man becomes castrate resistant. In clinical trials it has shown that it extends life when compared to placebo. The use of Provenge has raised many questions, the two most common ones are why PSA and disease progression continues while receiving this treatment (see post at for an explanation) [...]
There are now two new, additional sites added to the Early Access Trial of the investigational treatment known as Radium-233 or Alpharadin for men with castrate resistant prostate cancer with multiple bone metastases. This post contains the most up to date and accurate information, the clinical trials.gov site is NOT currently accurate. Additionally, there are [...]
A comprehensive study of prostate cancer tissue done in the UK has revealed that a completely new gene network takes over driving the cancer in men who are castrate resistant. The research was published in Cancer Cell. Researchers at the Cancer Research UK Cambridge Research Institute, at the University of Cambridge studied tissue samples from [...]
Mortality prospects after a prostate cancer recurrences following a radical prostatectomy has always been assumed to be directly related to the early development of metastases. A study from Melbourne Australia indicates that men with low-risk prostate cancer have good mortality prospects even when they experience early biochemical recurrence. The first author of the study, Anthony [...]
